Role of biomarkers in the diagnosis of inflammatory bowel disease

Expert Opinion on Medical Diagnostics

Volumn 1, Issue 4, 2007, Pages 481-488

  Vermeire, Severine ^a   Assche, Gert Van ^a   Rutgeerts, Paul ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

antimicrobial peptides; biomarkers; C reactive protein; calprotectin; Crohns disease; fecal markers; inflammatory bowel disease; lactoferrin; ulcerative colitis

Indexed keywords

EID: 80052119404     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.1.4.481     Document Type: Article

References (53)

1. BALLOU SP, KUSHNER I: C-reactive protein and the acute phase response. Adv. Intern. Med. (1992) 37 : 313-336.
2. GABAY C, KUSHNER I: Acute-phase proteins and other systemic responses to Inflammation. N. Engl. J. Med. (1999) 340 : 448-454. (Pubitemid 29084777)
3. PEPYS MB: C-reactive protein fi fty years on. Lancet (1981) 1 : 653-657.
4. FAGAN EA, DYCK RF, MATON PN et al. : Serum levels of C-reactive protein in Crohnïs disease and ulcerative colitis. Eur. J. Clin. Invest. (1982) 12 : 351-359. (Pubitemid 12024511)
5. NIEDERAU C, BACKMERHOFF F, SCHUMACHER B, NIEDERAU C: Inflammatory mediators and acute phase proteins in patients with Crohnïs disease and ulcerative colitis. Hepatogastroenterology (1997) 44 : 90-107. (Pubitemid 27096020)
6. SAVERYMUTTU SH, HODGSON HJ, CHADWICK VS, PEPYS MB: Differing acute phase responses in Crohnïs disease and ulcerative colitis. Gut (1986) 27 : 809-813. (Pubitemid 16058500)
7. SOLEM CA, LOFTUS EV Jr, TREMAINE WJ et al. : Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in Inflammatory bowel disease. Inflamm. Bowel Dis. (2005) 11 : 707-712. (Pubitemid 41271173)
8. GROSS V, ANDUS T, CAESAR I, ROTH M, SCHOLMERICH J: Evidence for continuous stimulation of interleukin-6 production in Crohnïs disease. Gastroenterology (1992) 102 : 514-519.
9. CARLSON CS, ALDRED SF, LEE PK et al. : Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am. J. Hum. Genet. (2005) 77 : 64-77. (Pubitemid 40848037)
10. RUSSELL AI, CUNNINGHAME GRAHAM DS, SHEPHERD C et al. : Polymorphism at the C-reactive protein locus Influences gene expression and predisposes to systemic lupus erythematosus. Hum. Mol. Genet. (2004) 13 : 137-147. (Pubitemid 38072141)
11. THALMAIER D, DAMBACHER J, SEIDERER J et al. : The +1059G/C polymorphism in the C-reactive protein (CRP) gene is associated with involvement of the terminal ileum and decreased serum CRP levels in patients with Crohnïs disease. Aliment. Pharmacol. Ther. (2006) 24 : 1105-1115. (Pubitemid 44386536)
12. SZALAI AJ, MCCRORY MA, COOPER GS, WU J, KIMBERLY RP: Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun. (2002) 3 : 14-19. (Pubitemid 38961100)
13. KOZLOWSKI P, MILLER DT, ZEE RY et al. : Lack of association between genetic variation in 9 innate immunity genes and baseline CRP levels. Ann. Hum. Genet. (2006) 70 (Part 5): 574-586. (Pubitemid 44173369)
14. WILLOT S, VERMEIRE S, OHRESSER M et al. : No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infl iximab treatment in Crohnïs disease. Pharmacogenet. Genomics (2006) 16 : 37-42. (Pubitemid 41803875)
15. POULLIS AP, ZAR S, SUNDARAM KK et al. : A new, highly sensitive assay for C-reactive protein can aid the differentiation of Inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders. Eur. J. Gastroenterol. Hepatol. (2002) 14 : 409-412. (Pubitemid 34439041)
16. ZILBERMAN L, MAHARSHAK N, ARBEL Y et al. : Correlated expression of high-sensitivity C-reactive protein in relation to disease activity in Inflammatory bowel disease: lack of differences between Crohnïs disease and ulcerative colitis. Digestion (2006) 73 : 205-209. (Pubitemid 44448880)
17. OSEI-BIMPONG A, MEEK JH, LEWIS SM: ESR or CRP? A comparison of their clinical utility. Hematology (2007) 12 : 353-357. (Pubitemid 47180665)
18. BJERRUM OW, NISSEN MH, BORREGAARD N: Neutrophil beta-2 microglobulin: an Inflammatory mediator: Scand. J. Immunol. (1990) 32 : 233-242. (Pubitemid 20282378)
19. JENSEN KB, JARNUM S, KOUDAHL G, KRISTENSEN M: Serum orosomucoid in ulcerative colitis: its relation to clinical activity, protein loss, and turnover of albumin and IgG. Scand. J. Gastroenterol. (1976) 11 : 177-183.
20. CONSIGNY Y, MODIGLIANI R, COLOMBEL JF et al. ; GROUPE DïETUDES THÉRAPEUTIQUES DES AFFECTIONS INFLAMMATOIRES DIGESTIVES (GETAID): A simple biological score for predicting low risk of short-term relapse in Crohnïs disease. Inflamm. Bowel Dis. (2006) 12 : 551-557.
21. FLORIN TH, PATERSON EW, FOWLER EV, RADFORD-SMITH GL: Clinically active Crohnïs disease in the presence of a low C-reactive protein. Scand. J. Gastroenterol. (2006) 41 : 306-311.
22. DENIS MA, REENAERS C, FONTAINE F, BELAÏCHE J, LOUIS E: Assessment of endoscopic activity index and biological Inflammatory markers in clinically active Crohnïs disease with normal C-reactive protein serum level. Inflamm. Bowel Dis. (2007) 13 : 1100-1105. (Pubitemid 47402593)
23. LANDERS CJ, COHAVY O, MISRA R et al. : Selected loss of tolerance evidenced by Crohnïs disease-associated immune responses to auto- and microbial antigens. Gastroenterology (2002) 123 : 689-699. (Pubitemid 34977074)
24. TARGAN SR, LANDERS CJ, YANG H et al. : Antibodies to CBir1 fl agellin defi ne a unique response that is associated independently with complicated Crohnïs disease. Gastroenterology (2005) 128 : 2020-2028. (Pubitemid 40824710)
25. DOTAN I, FISHMAN S, DGANI Y et al. : Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohnïs disease. Gastroenterology (2006) 131 : 366-378. (Pubitemid 44142445)
26. TERJUNG B, SPENGLER U, SAUERBRUCH T, WORMAN HJ: ïAtypical p-ANCAï in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology (2000) 119 : 310-322. (Pubitemid 30621981)
27. MOW WS, VASILIAUSKAS EA, LIN YC et al. : Association of antibody responses to microbial antigens and complications of small bowel Crohnïs disease. Gastroenterology (2004) 126 : 414-424. (Pubitemid 38182298)
28. FERRANTE M, HENCKAERTS L, JOOSSENS M et al. : New serological markers in Inflammatory bowel disease are associated with complicated disease behaviour. Gut (2007) [Epub ahead of print].
29. PAPP M, ALTORJAY I, NORMAN GL et al. : Seroreactivity to microbial components in Crohnïs disease is associated with ileal involvement, nonInflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. Inflamm. Bowel Dis. (2007) 13 : 984-992. (Pubitemid 47309970)
30. PATEL RT, STOKES R, BIRCH D, IBBOTSON J, KEIGHLEY MR: Influence of total colectomy on serum antineutrophil cytoplasmic antibodies in Inflammatory bowel disease. Br. J. Surg. (1994) 81 : 724-726. (Pubitemid 24192110)
31. KUISMA J, JÄRVINEN H, KAHRI A, FÄRKKILÄM: Factors associated with disease activity of pouchitis after surgery for ulcerative colitis. Scand. J. Gastroenterol. (2004) 39 : 544-548. (Pubitemid 38916259)
32. FLESHNER PR, VASILIAUSKAS EA, KAM LY et al. : High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut (2001) 49 (5): 671-677. (Pubitemid 32989204)
33. AISENBERG J, LEGNANI PE, NILUBOL N et al. : Are pANCA, ASCA, or cytokine gene polymorphisms associated with pouchitis? Long-term follow-up in 102 ulcerative colitis patients. Am. J. Gastroenterol. (2004) 99 (3): 432-441. (Pubitemid 38524119)
34. FERRANTE M, DECLERCK S, PENNINCKX F et al. : Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. JCC (In Press).
35. DUBINSKY MC, OFMAN JJ, URMAN M, TARGAN SR, SEIDMAN EG: Clinical utility of serodiagnostic testing in suspected pediatric Inflammatory bowel disease. Am. J. Gastroenterol. (2001) 96 : 758-765. (Pubitemid 32240727)
36. JOOSSENS S, REINISCH W, VERMEIRE S et al. : The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology (2002) 122 : 1242-1247. (Pubitemid 34465166)
37. JOOSSENS S, COLOMBEL JF, LANDERS C et al. : Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis. Gut (2006) 55 : 1667-1669. (Pubitemid 44629225)
38. ISRAELI E, GROTTO I, GILBURD B et al. : Anti- Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of Inflammatory bowel disease. Gut (2005) 54 : 1232-1236. (Pubitemid 41192480)
39. DEVLIN SM, YANG H, IPPOLITI A et al. : NOD2 variants and antibody response to microbial antigens in Crohnïs disease patients and their unaffected relatives. Gastroenterology (2007) 132 : 576-586. (Pubitemid 46274655)
40. HENCKAERTS LC, PIERIK M, JOOSSENS M, FERRANTE M, RUTGEERTS PJ, VERMEIRE S: Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with Inflammatory bowel disease. Gut (2007) 56 (11): 1536-1542. (Pubitemid 350033192)
41. ANGRIMAN I, SCARPA M, DïINCÀ R et al. : Enzymes in feces: useful markers of chronic Inflammatory bowel disease. Clin. Chim. Acta (2007) 381 : 63-68. (Pubitemid 46719135)
42. WALKER TR, LAND ML, KARTASHOV A et al. : Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with Inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. (2007) 44 : 414-422. (Pubitemid 46573222)
43. LANGHORST J, ELSENBRUCH S, MUELLER T et al. : Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm. Bowel Dis. (2005) 11 : 1085-1091. (Pubitemid 41682565)
44. LUNDBERG JO, HELLSTRÖM PM, FAGERHOL MK, WEITZBERG E, ROSETH AG: Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of Inflammatory bowel disease. Nat. Clin. Pract. Gastroenterol. Hepatol. (2005) 2 : 96-102.
45. SUGI K, SAITOH O, HIRATA I, KATSU K: Fecal lactoferrin as a marker for disease activity in Inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am. J. Gastroenterol. (1996) 91 : 927-934. (Pubitemid 26143531)
46. TIBBLE JA, SIGTHORSSON G, FOSTER R et al. : High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut (1999) 45 : 362-366. (Pubitemid 29400711)
47. ROSETH AG, SCHMIDT PN, FAGERHOL MK: Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with Inflammatory bowel disease. Scand. J. Gastroenterol. (1999) 34 : 50-54. (Pubitemid 29074787)
48. FAGERBERG UL, LOOF L, MYRDAL U, HANSSON LO, FINKEL Y: Colorectal Inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J. Pediatr. Gastroenterol. Nutr. (2005) 40 : 450-455. (Pubitemid 40489572)
49. RØSETH AG, AADLAND E, GRZYB K: Normalization of faecal calprotectin: a predictor of mucosal healing in patients with Inflammatory bowel disease. Scand. J. Gastroenterol. (2004) 39 : 1017-1020. (Pubitemid 39388470)
50. THJODLEIFSSON B, SIGTHORSSON G, CARIGLIA N et al. : Subclinical intestinal Inflammation: an inherited abnormality in Crohnïs disease relatives? Gastroenterology (2003) 124 : 1728-1737. (Pubitemid 36666769)
51. DE JONG NS, LEACH ST, DAY AS: Fecal S100A12: a novel noninvasive marker in children with Crohnïs disease. Inflamm. Bowel Dis. (2006) 12 : 566-572. (Pubitemid 43977737)
52. KAISER T, LANGHORST J, WITTKOWSKI H et al. : Fecal S100A12 as a non-invasive marker distinguishing Inflammatory bowel disease from irritable bowel syndrome. Gut (2007) 56 (12): 1706-1713. (Pubitemid 350206297)
53. SCHOEPFER AM, TRUMMLER M, SEEHOLZER P, SEIBOLD-SCHMID B, SEIBOLD F: Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies . Inflamm. Bowel Dis. (2007) (In Press).